Dynavax Technologies Valuation
| DVAX Stock | USD 13.41 0.01 0.07% |
At this time, the firm appears to be fairly valued. Dynavax Technologies shows a prevailing Real Value of $13.16 per share. The current price of the firm is $13.41. Our model computes the value of Dynavax Technologies from reviewing the firm fundamentals such as Current Valuation of 1.19 B, profit margin of 0.1 %, and Shares Outstanding of 124.07 M as well as analyzing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Dynavax Technologies' price fluctuation is very steady at this time. Calculation of the real value of Dynavax Technologies is based on 3 months time horizon. Increasing Dynavax Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Dynavax Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dynavax Stock. However, Dynavax Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.41 | Real 13.16 | Hype 13.41 | Naive 13.44 |
The intrinsic value of Dynavax Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Dynavax Technologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Dynavax Technologies helps investors to forecast how Dynavax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dynavax Technologies more accurately as focusing exclusively on Dynavax Technologies' fundamentals will not take into account other important factors: Dynavax Technologies Total Value Analysis
Dynavax Technologies is currently forecasted to have valuation of 1.19 B with market capitalization of 1.67 B, debt of 250.24 M, and cash on hands of 518.17 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Dynavax Technologies fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.19 B | 1.67 B | 250.24 M | 518.17 M |
Dynavax Technologies Investor Information
About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Dynavax Technologies was currently reported as 4.76. The company had not issued any dividends in recent years. Dynavax Technologies had 1:10 split on the 10th of November 2014. Based on the key indicators related to Dynavax Technologies' liquidity, profitability, solvency, and operating efficiency, Dynavax Technologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Dynavax Technologies Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Dynavax suggests not a very effective usage of assets in February.Dynavax Technologies Ownership Allocation
The majority of Dynavax Technologies outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dynavax Technologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dynavax Technologies. Please pay attention to any change in the institutional holdings of Dynavax Technologies as this could imply that something significant has changed or is about to change at the company.Dynavax Technologies Profitability Analysis
The company reported the previous year's revenue of 277.25 M. Net Income was 27.31 M with profit before overhead, payroll, taxes, and interest of 168.99 M.About Dynavax Technologies Valuation
Our relative valuation model uses a comparative analysis of Dynavax Technologies. We calculate exposure to Dynavax Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Dynavax Technologies's related companies.Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Dynavax Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 311 people.
Dynavax Technologies Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 133.3 M | |
| Quarterly Earnings Growth Y O Y | 0.208 | |
| Forward Price Earnings | 38.0228 |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.